Long-term follow-up of people with wet macular degeneration from a gene therapy study
Watches people with wet age-related macular degeneration for safety over up to 5 years.
Plain-language title generated from the registry record
Registry title: A Long-term Follow up Study of EXG102-031 in Participants With wAMD
Key facts
- Where
- Beijing, ChinaSee the site
Where in China
- Peking University People's HospitalBeijing, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Guangzhou Jiayin Biotech Ltd
- Trial code
- NCT06859515
- Record updated
- 15 August 2025
- Original description
This is a long-term, safety and efficacy follow-up study of patients in the EXG102-031-111 gene therapy clinical trial for wAMD. Patients will complete visits from the parent study, and then into this long-term follow-up study for continuous safety monitoring for up to 5 years.Read full original descriptionShow less
A Long-term Follow-up Study to Evaluate the Injection of EXG102-031 Ophthalmic Injection in Participants With Wet Age-related Macular Degeneration (wAMD).
This is a long-term, safety and efficacy follow-up study of patients in the EXG102-031-111 gene therapy clinical trial for wAMD. Patients will complete visits from the parent study, and then into this long-term follow-up study for continuous safety monitoring for up to 5 years.
Inclusion: Previously received treatment with EXG102-031 in the study (EXG102-031-111); Paticipantes are informed consent and willingness to follow protocol procedures.
Exclusion: Paticipantes are unwilling or unable to participate in long-term follow-up.